Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase

International Journal of Cancer

Volumn 114, Issue 1, 2005, Pages 19-31

  Wang, Feng Qiang ^a   So, John ^a   Reierstad, Scott ^a   Fishman, David A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gelatinase A MMP 2; Gelatinase B MMP 9; IL 8; Matrilysin; Ovarian cancer; Tissue inhibitor of MMP (TIMP) 2; VEGF

Indexed keywords

GELATINASE; GELATINASE B; ILOMASTAT; INTERLEUKIN 8; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; PROGELATINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CELL IMMORTALIZATION; CELL INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LATENT PERIOD; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STATISTICAL SIGNIFICANCE; TISSUE SECTION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA; CELL LINE, TUMOR; COLLAGENASES; DIPEPTIDES; ENZYME ACTIVATION; ENZYME PRECURSORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GELATINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 13244287807     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20697     Document Type: Article

References (46)

1. Maughan K. Specific keynote: in the shadow of illness-supporting women with ovarian cancer. Gynecol Oncol 2003;88:S129-33; discussion S34-5.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64, 1.
3. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Reich R. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 2002;187:39-45.
4. Liotta LA, Kohn EC. Stromal therapy: the next step in ovarian cancer treatment. J Natl Cancer Inst 2002;94:1113-4.
5. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
6. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66.
7. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270:5331-8.
8. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1996;16:150-9.
9. Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 2003;200:448-64.
10. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14.
11. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M, Reich R. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17:799-808.
12. Ghosh S, Wu Y, Stack MS. Ovarian cancer-associated proteinases. Cancer Treat Res 2002;107:331-51.
13. Wu X, Li H, Kang L, Li L, Wang W, Shan B. Activated matrix metalloproteinase-2-a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 2002;84:126-34.
14. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7:2396-404.
15. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224-9.
16. Lengyel E, Schmalfeldt B, Konik E, Spathe K, Harting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001;82:291-8.
17. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 2001;61:3194-9.
18. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003;22:145-52.
19. Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A, Atomi Y. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001;84:1317-21.
20. Fingleton BM, Heppner Goss KJ, Crawford HC, Matrisian LM. Matrilysin in early stage intestinal tumorigenesis. Apmis 1999;107:102-10.
21. Pokorny RM, Hunt L, Galandiuk S. What's new with tumor markers for colorectal cancer? Dig Surg 2000;17:209-15.
22. Zeng ZS, Shu WP, Cohen AM, Guillem JG. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 2002;8:144-8.
23. Ellerbroek SM, Fishman DA, Kearns AS, Bafetti LM, Stack MS. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res 1999;59:1635-41.
24. Karlan BY, Amin W, Band V, Zurawski VR Jr, Littlefield BA. Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol Oncol 1988;31:103-12.
25. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 1994;71:510-8.
26. Zhao YG, Xiao AZ, Newcomer RG, Park HI, Kang T, Chung LW, Swanson MG, Zhau HE, Kurhanewicz J, Sang QX. Activation of progelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 2003;278:15056-64.
27. Barille S, Bataille R, Rapp MJ, Harousseau JL, Amiot M. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 1999;163:5723-8.
28. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 2002;192:160-70.
29. Bernardo MM, Fridman R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 2003;374:739-45.
30. Worley JR, Thompkins PB, Lee MH, Hutton M, Soloway P, Edwards DR, Murphy G, Knauper V. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem J 2003;372:799-809.
31. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 1992;31:7152-4.
32. Agren MS, Mirastschijski U, Karlsmark T, Saarialho-Kere UK. Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp Dermatol 2001;10:337-48.
33. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stack MS. Characterization of gelatinase linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 1996;62:89-99.
34. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003;20:161-9.
35. Lin SW, Lee MT, Ke FC, Lee PP, Huang CJ, Ip MM, Chen L, Hwang JJ. TGFβ1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin Exp Metastasis 2000;18:493-9.
36. Ueda M, Terai Y, Kumagai K, Ueki K, Yamaguchi H, Akise D, Ueki M. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol Oncol 2001;82:162-6.
37. Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 1998;78:331-7.
38. Shibata K, Kikkawa F, Nawa A, Suganuma N, Hamaguchi M. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 1997;57:5416-20.
39. Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 2000;60:4745-51.
40. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, Wang Y, Yan Y, Clarke J, O'Brien TJ. The matrix metalloprotease pump-1 (MMP-7, matrilysin): a candidate marker/target for ovarian cancer detection and treatment. Tumour Biol 1999;20:88-98.
41. Shigemasa K, Tanimoto H, Sakata K, Nagai N, Parmley TH, Ohama K, O'Brien TJ. Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol 2000;17:52-8.
42. von Bredow DC, Cress AE, Howard EW, Bowden GT, Nagle RB. Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. Biochem J 1998;331:965-72.
43. Nakamura H, Fujii Y, Ohuchi E, Yamamoto E, Okada Y. Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. Eur J Biochem 1998;253:67-75.
44. Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, Okada Y. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995;270:6691-7.
45. Sang QA, Bodden MK, Windsor LJ. Activation of human progelatinase A by collagenase and matrilysin: activation of procollagenase by matrilysin. J Protein Chem 1996;15:243-53.
46. Itoh Y, Ito A, Iwata K, Tanzawa K, Mori Y, Nagase H. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem 1998;273:24360-7.